NEW YORK (GenomeWeb News) – NextGen has entered the gene-synthesis market after licensing Gene Oracle's GeneIOS gene-synthesis products and services, NextGen said today.
Under the agreement, NextGen will incorporate the GeneIOS technology into a new generation of ContractExpress products. The company will offer the combined technology as part of its fee-for-service offering.
NextGen will also offer GeneIOS as a standalone gene-synthesis product in the gene-to-protein development market.
NextGen expects to complete the technology transfer in the current quarter. NextGen will pay Gene Oracle technology transfer fees and ongoing royalty payments from commercial activities involving GeneIOS.
Additional details were not disclosed.